#Industry News
Raycome have Landed in Nearly 10,000 Medical Institutions
The new gold standard non-invasive blood pressure measurement technology
How to accurately measure blood pressure has attracted much attention from academic and medical circles. The current gold standard for noninvasive blood pressure measurement is the Coriolis method, the mercury sphygmomanometer.
Mercury, the scientific name is mercury, is a toxic substance. In 2013, representatives of 87 countries and regions, including China, signed the Minamata Convention, an international convention aimed at controlling and reducing mercury emissions. On August 16, 2017, the Convention entered into force in the State party. According to a joint announcement issued by the Ministry of Environmental Protection, the Ministry of Foreign Affairs and other departments, from the effective date, the mining of new primary mercury mines is prohibited. In addition, the Convention requires States parties to ban the production and import and export of mercury-containing products from 2020. The regulations that have an important impact on mercury sphygmomanometers are: from January 1, 2026, the production of mercury-containing sphygmomanometers is prohibited.
The gold standard non-invasive blood pressure measurement mercury sphygmomanometer is destined to withdraw from the historical stage, then who should lead the future of non-invasive blood pressure measurement? Let’s take a look at the current popular electronic sphygmomanometers.
Most electronic sphygmomanometers use high-sensitivity sensors in the cuff to measure blood pressure using the oscillometric method. It can automatically record the blood flow in the arteries and convert it into a digital form. It does not require a stethoscope when measuring, which is very convenient.
However, the oscillometric method used in electronic sphygmomanometers has certain shortcomings. The oscillometric method is a statistical measurement method and is not suitable for the following people: obese people; arrhythmias; extremely weak pulses, severe breathing difficulties and hypothermia Patients with a heart rate lower than 40 beats per minute or higher than 240 beats per minute; patients with rapid changes in blood pressure such as major bleeding, hypovolemia, shock; patients with Parkinson’s disease. In addition, the unified textbook of national metrology technology regulations clearly states that wrist and finger-type electronic sphygmomanometers are not suitable for diabetes, hypertension, and the elderly.
The applicable population of the electronic sphygmomanometer limits its possibility of becoming the gold standard. Fortunately, there are already innovative non-invasive blood pressure measurement methods in China, namely pulse wave blood pressure measurement. Pulse wave blood pressure measurement is a new generation of accurate blood pressure measurement technology developed by Dr. Wu Xiaoguang and his research team at Tsinghua University. It has obtained international and domestic invention patents. The pulse wave sphygmomanometer developed by Shenzhen Raycome Technology Co., Ltd. based on the pulse wave blood pressure measurement method is used for non-invasive accurate blood pressure measurement.
The pulse wave sphygmomanometer uses an upstream balloon and a downstream pulse wave detection method instead of the Coriolis method. Pulse waves can truly represent the state of blood flow. Multi-point measurement is used instead of single-point measurement, and the intrinsic relationship and change rules between points near the systolic and diastolic pressure points are calculated using approximation and fitting calculation methods to calculate the true systolic and diastolic pressure values. Continuous measurement of discontinuous events can measure the blood pressure between two beats of the heart.
(Photo courtesy of the enterprise)
The entire measurement process does not require manual intervention, and avoids subjective errors. The calculation of the blood pressure value relies on the internal relationship and change rules between the points near the systolic and diastolic pressure points, rather than based on empirical statistics, which avoids measurement errors caused by individual differences.
At present, pulse wave sphygmomanometers have been recognized by authoritative academic institutions such as the National Cardiovascular Center, the Chinese Hypertension Association, and the National Hypertension Big Data Joint Laboratory.
Some experts said: “The non-invasive precision pulse wave sphygmomanometer creatively uses pulse wave detection technology, which solves the problem of non-invasive and precise blood pressure measurement for more than 100 years since the invention of the Coriolis sphygmomanometer, and makes up for the international non-invasive precision blood pressure measurement. Blank, a new generation of blood pressure monitors that replace mercury blood pressure monitors. ”
Compared with other non-invasive methods for measuring blood pressure, pulse wave sphygmomanometers have the advantages of accurate measurement, unlimited application to the population, environmental protection and no mercury, and have great potential in the future.
Hypertension market is huge, Raycome launches total blood pressure service
According to the “Healthy China Action (2019-2030)” released on July 9, 2019, there are 270 million people with hypertension in the country, which seriously affects people’s health. To ensure the success of the Healthy China goal, the Healthy China Action Promotion Committee gives recommendations for blood pressure monitoring, blood lipid testing, self-health management, diet, and exercise.
For patients with hypertension, blood pressure monitoring is very important. Monitoring blood pressure can understand the patient’s physical condition in real time, and is also conducive to health management. Throughout China’s hypertension health management, the current awareness rate of hypertension is close to 50%, but the control rate is less than 17%. The reason why the control rate is so low is that it is difficult for the monitoring technology to sink, and new technologies for hypertension management are not popular at the grassroots level.
With the acceleration of population aging and changes in lifestyles, the incidence of hypertension in China is rising rapidly, and it is imminent to manage blood pressure health for patients with hypertension. The “Healthy China Action (2019-2030)” cardiovascular disease prevention and control action clearly states that by 2022 and 2030, the hypertension awareness rate of residents aged 30 years and over is not less than 55% and 65%, and the standardized management rate of hypertension patients The treatment rate and control rate of hypertension have continued to increase, not less than 60% and 70% respectively. At the social and government levels, the first-time blood pressure measurement system for people over 35 years of age has been comprehensively implemented, and strategies for co-management of hypertension, hyperglycemia, and hyperlipidemia have been promoted.
The first problem with blood pressure management is blood pressure monitoring. Mercury sphygmomanometer will exit the stage of history, an oscillometric electronic sphygmomanometer is not suitable for everyone, and pulse wave sphygmomanometer is trusted by authoritative academic institutions such as the National Cardiovascular Center, China Hypertension Alliance, National Hypertension Big Data Joint Laboratory, No environmental problems, accurate measurement, has been used in nearly 10,000 medical institutions across the country. The pulse wave sphygmomanometer was developed and produced by Raycome, which was founded in 2008.
Raycome is a high-tech company specializing in accurate blood pressure measurement technology. Its pulse wave sphygmomanometer has a certain right to speak in the market. Zhou Wei, general manager of Raycome, said: “In the market segments of health all-in-one, smart medical, and hemodialysis, the pulse wave sphygmomanometer market share is far ahead.”
The reason why the blood pressure monitoring field was chosen was because the Raycome team saw a huge market in the field of hypertension, and because the Raycome team hoped that the blood pressure field could be completed domestically instead of imported. To this end, Raycome deployed an integrated blood pressure service.
Zhou Wei explained: “The integrated blood pressure service includes two aspects. First, the blood pressure monitoring service we provide covers a wide range of scenarios, including outpatient screening, 24-hour ambulatory blood pressure monitoring, hospitalization measurement, and home monitoring. Second, we have complete equipment, including pulse wave medical automatic sphygmomanometers, ambulatory blood pressure monitors and pulse wave home blood pressure monitors suitable for remote blood pressure monitoring at home. ”
In addition, Raycome has laid out blood pressure management. High blood pressure is difficult to cure, and more importantly, chronic disease management outside the hospital. Raycome’s wholly-owned subsidiary, Medical Customer Network, is responsible for blood pressure management business. At present, it has reached strategic cooperation with a number of large enterprises such as HKUST Xunfei, Sannuo, and Lianying.
Focus on hospital channels, build e-commerce sales network, and expand international market
“Controlling blood pressure starts with ‘accurate’ measurement!” Zhou Wei told reporters that professional institutions such as hospitals place great importance on the accuracy of blood pressure detection. It is enough to explain that the electronic sphygmomanometer has not entered the hospital and other professional institutions for many years after entering the market.
Based on this, Raycome first opened the hospital channel with a high accuracy of pulse wave measurement. At present, Raycome has a price advantage in products, an accuracy advantage in measurement technology, and an advantage in invention patents. In addition, the state supports hospitals to purchase domestic equipment first. Against the background of import substitution, Raycome is rapidly increasing its market share. Zhou Wei said: “Whether it is technology or product layout, it is obvious that we replace imports.”
So far, Raycome’s sphygmomanometers have been used in nearly 10,000 medical institutions, and many provinces have achieved large-scale coverage. Raycome sphygmomanometers are already used in many cardiology or cardiovascular specialty hospitals. Zhou Wei said: “The recognition of professional organizations is because these professional organizations need accurate measurement equipment, and pulse wave sphygmomanometers can fully meet these needs.”
In addition to the hospital side, Ruiguang Kangkang has deployed the C-side market. Raycome is deployed on e-commerce platforms such as Tmall and JD.com and sells directly to the C-end. Zhou Wei introduced: “In the double eleven of 2019, the sales volume of pulse wave sphygmomanometer ranked fourth in the Tmall same category sales list. In the future, when the hospital channel affects the C-end market, using high dimensions to fight low dimensions, things will change. It’s a lot easier, and pulse wave sphygmomanometers are likely to usher in an explosion. ”
Zhou Wei also disclosed: “Raycome has signed more than ten national agents, and the products are exported to all parts of the world, occupying more shares in the international market. In addition, Raycome will increase its layout in the international market next year.”
At present, the state promotes the first blood pressure measurement system for people over the age of 35, and urges medical institutions at all levels to measure blood pressure on patients. Zhou Wei said: “This is equivalent to measuring blood pressure as the standard treatment for medical treatment. Just as before, patients need to take a body temperature when they go to the hospital; today, when measuring body temperature, they also need to measure blood pressure. Blood pressure meters, like thermometers, will become medical treatment at all levels. Institutional standard. ”
This brings not only a huge blood pressure measurement market, but also an increase in awareness of hypertension. As hypertension gets more and more attention, sphygmomanometers will also become a family standing product. Therefore, in the education market, Raycome still mainly focuses on hospital channels. When Raycome products win strategic brand influence in hospital channels, patients will also choose Raycome products. After all, patients trust doctors more and trust the products they use. Zhou Wei said: “After a product is recognized in the hospital, it is natural for it to be promoted in the C-end market, and the promotion will be simpler.”
Raycome’s products have covered nearly 10,000 medical institutions across the country. What are your plans for the future? Zhou Wei said: “We will adhere to the field of hypertension and develop products in two directions. First, high-end products, production of high-end medical devices, instead of imported products, to stabilize the hospital market. Second, product portability, such as Wearables, the Internet of Things. Currently, we have a layout in these areas. ”
In addition, Raycome plans to focus on hypertension and expand its development upstream and downstream, such as blood pressure management. Zhou Wei said: “The medical industry is vast and profound, and the field of hypertension requires companies like Raycome to focus on research.”
Finally, Zhou Wei said: “At present, we plan to start a new round of financing around the Spring Festival. The financing will be used to expand the market and increase market share.”
